September 20, 2026

Amneal Generic Lanreotide FDA Approval, Novo Denecimig CHMP for Hemophilia A, Lilly Inluriyo+Verzenio ESR1 Breast Cancer

Amneal generic lanreotide FDA approval + immediate launch, Novo denecimig CHMP for hemophilia A, Lilly Inluriyo+Verzenio FDA approval for ESR1-mutated BC.

5 stories · Covering regulatory, industry

Editor's Note

Sunday sits between two active regulatory weeks and the Monday September 21 Novo Capital Markets Day in London. The most consequential Friday news for the peptide franchise: Amneal Pharmaceuticals secured FDA approval for a generic lanreotide 120 mg injection referencing Ipsen's Somatuline Depot — a somatostatin analog peptide with $983 million in U.S. annual sales — and launched the day of approval under Competitive Generic Therapy designation, opening the first material pricing pressure the acromegaly and neuroendocrine-tumor peptide market has seen in years. Novo Nordisk secured a Thursday September 17 CHMP positive opinion for FREHEMGO (denecimig), a factor VIIIa-mimetic bispecific antibody for hemophilia A with once-monthly, every-two-week, or weekly subcutaneous dosing options and a prefilled pen at launch — potentially the second denecimig-class product to reach European patients after Roche's Hemlibra. Eli Lilly's Inluriyo (imlunestrant, oral SERD) plus Verzenio (abemaciclib, CDK4/6 inhibitor) received Friday FDA approval for adults with ER+/HER2−/ESR1-mutated advanced or metastatic breast cancer after prior endocrine-therapy progression — median PFS 11.1 months versus 5.5 months on Inluriyo monotherapy. Novartis received CHMP backing for Cosentyx (secukinumab, IL-17A inhibitor) in polymyalgia rheumatica, positioning it as the first IL-17 in this steroid-refractory population. And weekend previews of the Novo Capital Markets Day filed CEO Mike Doustdar's most direct 'the obesity market is not a zero-sum game' framing to date.

Regulatory

Amneal Pharmaceuticals Secures FDA Approval and Immediate Launch of Generic Lanreotide 120 mg Injection (Somatostatin Analog Peptide) with Competitive Generic Therapy Designation; Reference Product Somatuline Depot Had $983M in U.S. Annual Sales

Amneal Pharmaceuticals (NASDAQ: AMRX) announced Friday September 18, 2026 that the FDA approved and Amneal has immediately launched a generic lanreotide 120 mg / 0.5 mL sterile single-dose prefilled syringe injection referencing Ipsen's Somatuline Depot. Lanreotide is a long-acting somatostatin analog peptide indicated for adults with acromegaly, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome. The FDA granted Competitive Generic Therapy (CGT) designation — a 180-day marketing exclusivity for a first generic entrant in a market with limited competition. According to IQVIA data, U.S. annual sales of the reference product Somatuline Depot totaled $983 million for the 12 months ended July 2026. This is the first generic lanreotide to reach the U.S. market and opens material pricing competition for a peptide category that had been effectively single-source (Ipsen) for over 15 years since Somatuline Depot's original 2007 U.S. approval. Amneal joins a small group of peptide-generic producers with the technical capability to reproduce the depot-formulation octapeptide plus the extended-release delivery system.

#amneal-pharmaceuticals #amrx #generic-lanreotide #lanreotide-injection #somatostatin-analog #octapeptide #ipsen-reference-product #somatuline-depot-reference #competitive-generic-therapy #180-day-exclusivity #acromegaly #gep-nets #carcinoid-syndrome #983-million-us-market #first-generic-lanreotide #extended-release-formulation #peptide-generic

Regulatory

Novo Nordisk FREHEMGO (Denecimig, Factor VIIIa-Mimetic Bispecific Antibody) Receives Positive EU CHMP Opinion for Hemophilia A With or Without Inhibitors; Once-Monthly, Every-Two-Week, and Weekly SC Dosing Options

Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) received Thursday September 17, 2026 a positive EU CHMP opinion recommending marketing authorization for FREHEMGO (denecimig), the company's next-generation factor VIIIa-mimetic bispecific antibody, for treatment of hemophilia A (with or without factor VIII inhibitors) in adults and children. Denecimig offers flexible subcutaneous dosing including once-monthly, every-two-week, or weekly administration in a prefilled-pen presentation. Approval would position denecimig as the second bispecific-antibody FVIIIa mimetic in the European hemophilia A market after Roche's Hemlibra (emicizumab, first launched 2018) — potentially the first meaningful bispecific competition Roche has faced in the Hemlibra franchise. Novo Nordisk expects to launch denecimig in the first European countries in Q4 2026, with broader EU rollout beginning early 2027. The CHMP recommendation is based on data from the Phase 3 FRONTIER program including FRONTIER-2 (adults) and FRONTIER-4 (pediatric) trials. Sandoz-mAbxience separately announced Friday a Hemlibra-referenced biosimilar collaboration, adding a second layer of long-term competitive pressure to the Roche franchise.

#novo-nordisk #novo #nvo #frehemgo #denecimig #factor-viiia-mimetic #bispecific-antibody #hemophilia-a #with-and-without-inhibitors #monthly-biweekly-weekly-sc-dosing #prefilled-pen #chmp-positive-opinion #hemlibra-competitor #roche-emicizumab-context #frontier-2-frontier-4-phase-3 #q4-2026-eu-launch #sandoz-mabxience-biosimilar-context #non-peptide

Regulatory

FDA Approves Eli Lilly Inluriyo (Imlunestrant, Oral SERD) + Verzenio (Abemaciclib, CDK4/6 Inhibitor) Combination for ER+/HER2−/ESR1-Mutated Advanced or Metastatic Breast Cancer After Prior Endocrine Therapy; Median PFS 11.1 Months vs 5.5 Months on Monotherapy

The FDA approved Friday September 18, 2026 Eli Lilly's (NYSE: LLY) Inluriyo (imlunestrant, oral next-generation selective estrogen receptor degrader / SERD) in combination with Verzenio (abemaciclib, oral CDK4/6 inhibitor) for adults with estrogen-receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one prior line of endocrine therapy. ESR1 mutations are detected via the FDA-authorized Guardant360 CDx companion diagnostic (Guardant Health, NASDAQ: GH). Patients on the combination had median progression-free survival of 11.1 months versus 5.5 months on Inluriyo monotherapy — an approximately 2× improvement. This is Inluriyo's second FDA approval within a year after its September 2025 monotherapy approval in the same population and is the first FDA-approved oral-SERD + CDK4/6 inhibitor combination in this setting. The approval strengthens Lilly's breast-cancer franchise anchored by Verzenio ($6.3B 2025 global sales) and expands the addressable population for both agents.

#eli-lilly #lly #inluriyo #imlunestrant #oral-next-generation-serd #verzenio #abemaciclib #cdk4-6-inhibitor #er-positive-her2-negative #esr1-mutated-breast-cancer #advanced-metastatic-breast-cancer #guardant360-cdx-companion-diagnostic #guardant-health-gh #11-1-vs-5-5-month-mpfs #second-fda-approval-in-a-year #non-peptide

Regulatory

Novartis Cosentyx (Secukinumab, IL-17A Inhibitor Monoclonal Antibody) Receives Positive EU CHMP Opinion in Polymyalgia Rheumatica (PMR); First IL-17 Inhibitor in Class for This Steroid-Refractory Population

Novartis (NYSE: NVS; SIX: NOVN) announced Friday September 18, 2026 that the EMA's CHMP adopted a positive opinion recommending EU marketing authorization for Cosentyx (secukinumab, a fully human IgG1 monoclonal antibody against interleukin-17A) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to steroids or who experience relapse during steroid taper. Upon EC approval, Cosentyx would be the first IL-17A inhibitor licensed in Europe for PMR — a common inflammatory rheumatic disease in adults over 50 with limited advanced treatment options beyond long-term steroids (which carry significant morbidity). The recommendation is anchored on the REPLENISH Phase 3 trial: all primary and secondary endpoints were met across both Cosentyx 300 mg and 150 mg treatment arms, showing doubled sustained remission rates and steroid-sparing benefit versus placebo, with safety consistent with the established Cosentyx profile. European Commission decision is expected by November 2026. Cosentyx generated approximately $6.4 billion in 2025 global sales across its 10+ approved indications.

#novartis #nvs #novn #cosentyx #secukinumab #il-17a-inhibitor #monoclonal-antibody #polymyalgia-rheumatica #pmr #steroid-inadequate-response #chmp-positive-opinion #replenish-phase-3 #doubled-sustained-remission #steroid-sparing-effect #first-il-17-in-class-for-pmr #ec-decision-november-2026 #6-4-billion-2025-global-sales #non-peptide

Industry

Novo Nordisk Capital Markets Day Weekend Preview: CEO Mike Doustdar Frames Monday London Reset Around 'Obesity Is Not a Zero-Sum Game' and 'The Novo Way' Culture Framework

Weekend previews of the Monday September 21, 2026 Novo Capital Markets Day in London (webcast live from 09:00 BST / 10:00 CET, running to 15:30 BST / 16:30 CET) landed Saturday and Sunday framing CEO Mike Doustdar's most direct commentary to date on the semaglutide-vs-tirzepatide franchise dynamic. In a Reuters interview released Friday September 18, Doustdar characterized the obesity market as not a 'zero-sum game' as patients 'crave optionality,' rejecting the Morgan Stanley Underweight thesis (September 11 downgrade, DKK 250 target) that Wegovy's U.S. share erosion is structural. Doustdar's 'Novo Way' culture framework announced with the September 14 rebrand emphasizes customer focus, competitiveness, clarity, and care. Sell-side previews (TIKR, Bloomberg, Kontra Invest, TradingKey) frame CMD priorities as: managing the 2031 semaglutide loss of exclusivity, U.S. Wegovy pill script trajectory (>5 million total prescriptions as of August), the CagriSema U.S. obesity decision path (late 2026), the ziltivekimab HERMES/ATHENA terminations, the $1.4 billion Orbis Medicines Sept 17 macrocycle deal, and the Sept 16 Anthropic Claude Science R&D collaboration. NVO shares closed Friday at $42.97 (-0.23% weekly).

#novo-nordisk #novo #nvo #capital-markets-day-monday-september-21 #mike-doustdar-ceo #novo-way-culture-framework #reuters-doustdar-interview #not-a-zero-sum-game #morgan-stanley-underweight-context #2031-semaglutide-loss-of-exclusivity #wegovy-pill-5-million-context #cagrisema-late-2026 #ziltivekimab-context #orbis-medicines-context #anthropic-claude-context #glp-1